Autologous expansion rates and functional capacities according to Vγ9Vδ2 T-cell phenotype. (A) PBMCs from patients with AML (n = 43) were cultured with 1 μM zoledronate (ZOL) plus 200 U/mL rhIL-2 and 10 μg/mL rhIL-15 for 14 days. (B) Degranulation of Vγ9Vδ2 T cells expanded from PBMCs of patients with AML (n = 23) against autologous blasts pretreated or not with ZOL 50 μM and with or without the agonist anti-BTN3A 20.1 mAb. Results are presented as box plots (A) or as mean ± SD (B), and the statistical significance was established using a Mann-Whitney test (A-B) or a Friedman test followed by a Dunn's test (B). ∗∗P < .01; ∗∗∗∗P < .0001.